The Potential Drug Target and Biomarker PPRELID1: Unraveling the Undisclosed Complexity

Target Name: PRELID1

NCBI ID: G27166

PRELID1

The Potential Drug Target and Biomarker PPRELID1: Unraveling the Undisclosed Complexity

Prelid1, a highly conserved protein with structural similarity to the well-known protein Px19, has been identified as a potential drug target and biomarker in various diseases. Its unique structure, localization, and regulation make it an attractive candidate for further investigation. In this article, we will delve into the molecular mechanisms, clinical applications, and future prospects of this protein to highlight its implications as a drug target and biomarker.

Molecular Mechanisms

Prelid1 is a 25-kDa protein that is expressed in various tissues, including brain, heart, liver, and kidney. Its localization is highly dependent on the presence of specific post-translational modifications, such as phosphorylation and ubiquitination. These modifications not only give the protein its unique structure but also regulate its stability, localization, and interactions with other proteins.

Prelid1 has been shown to play a critical role in various physiological processes, including cell signaling, DNA damage repair, and cell adhesion. Its involvement in these processes has led to its potential as a drug target. By modulating its localization, stability, and interactions with other proteins, Prelid1 can be targeted by small molecules, antibodies, or other therapeutic agents to modulate its function and contribute to the development of various diseases.

Clinical Applications

Prelid1 has been identified as a potential drug target in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its potential as a drug target is based on its involvement in various signaling pathways and its unique structure.

In cancer, Prelid1 has been shown to be involved in cell signaling, angiogenesis, and drug resistance. Its expression is often increased in various types of cancer, including neuroendocrine, pancreatic, and breast cancers. Therefore, targeting Prelid1 with small molecules or antibodies has the potential to inhibit its functions and contribute to the development of these diseases.

In neurodegenerative diseases, Prelid1 has been linked to the pathology of various neurodegenerative disorders, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. Its expression is often increased in these disorders, and its presence in the brains of affected individuals has suggested that it may play a role in the pathology of these diseases. Therefore, targeting Prelid1 with small molecules or antibodies has the potential to modulate its function and contribute to the development of these disorders.

In autoimmune disorders, Prelid1 has been associated with the development and progression of various autoimmune diseases, including rheumatoid arthritis, lupus, and multiple sclerosis. Its expression is often increased in individuals with these disorders, and its presence in the tissues has suggested that it may contribute to the pathology of these disorders. Therefore, targeting Prelid1 with small molecules or antibodies has the potential to modulate its function and contribute to the development of these autoimmune disorders.

Future Prospects

The identification of Prelid1 as a potential drug target and biomarker has significant implications for future research. Further studies are needed to investigate its role in various diseases and its potential as a therapeutic agent.

One approach to targeting Prelid1 is to develop small molecules that can modulate its localization, stability, or interactions with other proteins. These small molecules can be tested for their efficacy in modulating Prelid1 function and their potential utility as therapeutic agents.

Another approach is to use antibodies to target Prelid1 and its localization. antibodies can be used to detect and localize Prelid1 in various tissues and to understand its regulation mechanisms.

In addition, computational modeling and structural bioinformatics can be

Protein Name: PRELI Domain Containing 1

Functions: Involved in the modulation of the mitochondrial apoptotic pathway by ensuring the accumulation of cardiolipin (CL) in mitochondrial membranes. In vitro, the TRIAP1:PRELID1 complex mediates the transfer of phosphatidic acid (PA) between liposomes and probably functions as a PA transporter across the mitochondrion intermembrane space to provide PA for CL synthesis in the inner membrane. Regulates the mitochondrial apoptotic pathway in primary Th cells. Regulates Th cell differentiation by down-regulating STAT6 thereby reducing IL-4-induced Th2 cell number. May be important for the development of vital and immunocompetent organs

The "PRELID1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PRELID1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets